<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24742193</PMID><DateCompleted><Year>2014</Year><Month>08</Month><Day>25</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1945-7170</ISSN><JournalIssue CitedMedium="Internet"><Volume>155</Volume><Issue>7</Issue><PubDate><Year>2014</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Endocrinology</Title><ISOAbbreviation>Endocrinology</ISOAbbreviation></Journal><ArticleTitle>Antiandrogen flutamide protects male mice from androgen-dependent toxicity in three models of spinal bulbar muscular atrophy.</ArticleTitle><Pagination><StartPage>2624</StartPage><EndPage>2634</EndPage><MedlinePgn>2624-34</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1210/en.2013-1756</ELocationID><Abstract><AbstractText>Spinal and bulbar muscular atrophy (SBMA) is a late-onset, progressive neurodegenerative disease linked to a polyglutamine (polyQ) expansion in the androgen receptor (AR). Men affected by SBMA show marked muscle weakness and atrophy, typically emerging midlife. Given the androgen-dependent nature of this disease, one might expect AR antagonists to have therapeutic value for treating SBMA. However, current work from animal models suggests otherwise, raising questions about whether polyQ-expanded AR exerts androgen-dependent toxicity through mechanisms distinct from normal AR function. In this study, we asked whether the nonsteroidal AR antagonist flutamide, delivered via a time-release pellet, could reverse or prevent androgen-dependent AR toxicity in three different mouse models of SBMA: the AR97Q transgenic (Tg) model, a knock-in (KI) model, and a myogenic Tg model. We find that flutamide protects mice from androgen-dependent AR toxicity in all three SBMA models, preventing or reversing motor dysfunction in the Tg models and significantly extending the life span in KI males. Given that flutamide effectively protects against androgen-dependent disease in three different mouse models of SBMA, our data are proof of principle that AR antagonists have therapeutic potential for treating SBMA in humans and support the notion that toxicity caused by polyQ-expanded AR uses at least some of the same mechanisms as normal AR before diverging to produce disease and muscle atrophy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Renier</LastName><ForeName>Kayla J</ForeName><Initials>KJ</Initials><AffiliationInfo><Affiliation>Neuroscience Program (K.J.R., S.M.T.-S., S.M.B., C.L.J.), Michigan State University, E Lansing, Michigan 48824-1101; College of Medicine (J.A.J.), Central Michigan University, Mt Pleasant Michigan 48859; Department of Neurology (M.K., H.A., G.S.), Nagoya University Graduate School of Medicine, Nagoya, Japan 466-8550; and Department of Pathology (J.P.C., H.S.K., A.P.L.), University of Michigan, Ann Arbor, Michigan 48109.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Troxell-Smith</LastName><ForeName>Sandra M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Johansen</LastName><ForeName>Jamie A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Katsuno</LastName><ForeName>Masahisa</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Adachi</LastName><ForeName>Hiroaki</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Sobue</LastName><ForeName>Gen</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Chua</LastName><ForeName>Jason P</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Sun Kim</LastName><ForeName>Hong</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Lieberman</LastName><ForeName>Andrew P</ForeName><Initials>AP</Initials></Author><Author ValidYN="Y"><LastName>Breedlove</LastName><ForeName>S Marc</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Jordan</LastName><ForeName>Cynthia L</ForeName><Initials>CL</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NS28421</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS028421</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS045195</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS076189</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS055746</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS055746</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F31 NS076189</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS045195</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>04</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Endocrinology</MedlineTA><NlmUniqueID>0375040</NlmUniqueID><ISSNLinking>0013-7227</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000726">Androgen Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000728">Androgens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011944">Receptors, Androgen</NameOfSubstance></Chemical><Chemical><RegistryNumber>26700-71-0</RegistryNumber><NameOfSubstance UI="C097188">polyglutamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>76W6J0943E</RegistryNumber><NameOfSubstance UI="D005485">Flutamide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000726" MajorTopicYN="N">Androgen Antagonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000728" MajorTopicYN="N">Androgens</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055534" MajorTopicYN="N">Bulbo-Spinal Atrophy, X-Linked</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005485" MajorTopicYN="N">Flutamide</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009919" MajorTopicYN="N">Orchiectomy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011944" MajorTopicYN="N">Receptors, Androgen</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019680" MajorTopicYN="N">Trinucleotide Repeat Expansion</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>8</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24742193</ArticleId><ArticleId IdType="pmc">PMC4060177</ArticleId><ArticleId IdType="doi">10.1210/en.2013-1756</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fischbeck KH. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature. 1991;352(6330):77&#x2013;79</Citation><ArticleIdList><ArticleId IdType="pubmed">2062380</ArticleId></ArticleIdList></Reference><Reference><Citation>Chevalier-Larsen ES, O'Brien CJ, Wang H, et al. Castration restores function and neurofilament alterations of aged symptomatic males in a transgenic mouse model of spinal and bulbar muscular atrophy. J Neurosci. 2004;24(20):4778&#x2013;4786</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729468</ArticleId><ArticleId IdType="pubmed">15152038</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Z, Dadgar N, Albertelli M, et al. Androgen-dependent pathology demonstrates myopathic contribution to the Kennedy disease phenotype in a mouse knock-in model. J Clin Invest. 2006;116(10):2663&#x2013;2672</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1564432</ArticleId><ArticleId IdType="pubmed">16981011</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuno M, Adachi H, Kume A, et al. Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron. 2002;35(5):843&#x2013;854</Citation><ArticleIdList><ArticleId IdType="pubmed">12372280</ArticleId></ArticleIdList></Reference><Reference><Citation>Johansen JA, Monks DA, Lieberman AP, et al. Recovery of function in a myogenic mouse model of spinal bulbar muscular atrophy. Neurobiol Dis. 2009;34(1):113&#x2013;120</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4209964</ArticleId><ArticleId IdType="pubmed">19211034</ArticleId></ArticleIdList></Reference><Reference><Citation>Monks DA, Johansen JA, Mo K, et al. Overexpression of wild-type androgen receptor in muscle recapitulates polyglutamine disease. Proc Natl Acad Sci USA. 2007;104(46):18259&#x2013;18264</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2084330</ArticleId><ArticleId IdType="pubmed">17984063</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinirons P, Rouleau GA. Administration of testosterone results in reversible deterioration in Kennedy's disease. J Neurol Neurosurg Psychiatry. 2008;79(1):106&#x2013;107</Citation><ArticleIdList><ArticleId IdType="pubmed">17056629</ArticleId></ArticleIdList></Reference><Reference><Citation>Banno H, Katsuno M, Suzuki K, et al. Phase 2 trial of leuprorelin in patients with spinal and bulbar muscular atrophy. Ann Neurol. 2009;65(2):140&#x2013;150</Citation><ArticleIdList><ArticleId IdType="pubmed">19259967</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeyama K, Ito S, Yamamoto A, et al. Androgen-dependent neurodegeneration by polyglutamine-expanded human androgen receptor in Drosophila. Neuron. 2002;35(5):855&#x2013;864</Citation><ArticleIdList><ArticleId IdType="pubmed">12372281</ArticleId></ArticleIdList></Reference><Reference><Citation>Furutani T, Takeyama K, Tanabe M, et al. Human expanded polyglutamine androgen receptor mutants in neurodegeneration as a novel ligand target. J Pharmacol Exp Ther. 2005;315(2):545&#x2013;552</Citation><ArticleIdList><ArticleId IdType="pubmed">16079302</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuno M, Adachi H, Doyu M, et al. Leuprorelin rescues polyglutamine-dependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy. Nat Med. 2003;9(6):768&#x2013;773</Citation><ArticleIdList><ArticleId IdType="pubmed">12754502</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt BJ, Greenberg CR, Allingham-Hawkins DJ, Spriggs EL. Expression of X-linked bulbospinal muscular atrophy (Kennedy disease) in two homozygous women. Neurology. 2002;59(5):770&#x2013;772</Citation><ArticleIdList><ArticleId IdType="pubmed">12221177</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischbeck KH. Kennedy disease. J Inherit Metab Dis. 1997;20(2):152&#x2013;158</Citation><ArticleIdList><ArticleId IdType="pubmed">9211187</ArticleId></ArticleIdList></Reference><Reference><Citation>Orr CR, Montie HL, Liu Y, et al. An interdomain interaction of the androgen receptor is required for its aggregation and toxicity in spinal and bulbar muscular atrophy. J Biol Chem. 2010;285(46):35567&#x2013;35577</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2975181</ArticleId><ArticleId IdType="pubmed">20826791</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuzaki Y, Nagai D, Ichimura E, Goda R, et al. Metabolism and hepatic toxicity of flutamide in cytochrome P450 1A2 knockout SV129 mice. J Gastroenterol. 2006;41(3):231&#x2013;239</Citation><ArticleIdList><ArticleId IdType="pubmed">16699857</ArticleId></ArticleIdList></Reference><Reference><Citation>Kemp MQ, Poort JL, Baqri RM, et al. Impaired motoneuronal retrograde transport in two models of SBMA implicates two sites of androgen action. Hum Mol Genet. 2011;20(22):4475&#x2013;4490</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3196895</ArticleId><ArticleId IdType="pubmed">21873607</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuloaga DG, Morris JA, Jordan CL, Breedlove SM. Mice with the testicular feminization mutation demonstrate a role for androgen receptors in the regulation of anxiety-related behaviors and the hypothalamic-pituitary-adrenal axis. Horm Behav. 2008;54(5):758&#x2013;766</Citation><ArticleIdList><ArticleId IdType="pubmed">18775430</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith E, Damassa DA, Davidson JM, eds. Hormone Administration: Peripheral and Intracranial Implants. New York: Academic Press; 1978. Meyer T, ed. Methods of Psychobiology. No. 3</Citation></Reference><Reference><Citation>Johansen JA, Troxell-Smith SM, Yu Z, et al. Prenatal flutamide enhances survival in a myogenic mouse model of spinal bulbar muscular atrophy. Neurodegener Dis. 2011;8(1&#x2013;2):25&#x2013;34</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3030474</ArticleId><ArticleId IdType="pubmed">20689246</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy JC, Srinivas S, Terris MK. Flutamide administration at 500 mg daily has similar effects on serum testosterone to 750 mg daily. J Androl. 2004;25(4):630&#x2013;634</Citation><ArticleIdList><ArticleId IdType="pubmed">15223852</ArticleId></ArticleIdList></Reference><Reference><Citation>Viguier-Martinez MC, Hochereau de Reviers MT, Barenton B, Perreau C. Endocrinological and histological changes induced by flutamide treatment on the hypothalamo-hypophyseal testicular axis of the adult male rat and their incidences on fertility. Acta Endocrinol (Copenh). 1983;104(2):246&#x2013;252</Citation><ArticleIdList><ArticleId IdType="pubmed">6314726</ArticleId></ArticleIdList></Reference><Reference><Citation>Sodersten P, Gray G, Damassa DA, Smith ER, Davidson JM. Effects of a non-steroidal antiandrogen on sexual behavior and pituitary-gonadal function in the male rat. Endocrinology. 1975;97(6):1468&#x2013;1475</Citation><ArticleIdList><ArticleId IdType="pubmed">1204574</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson RT, Schneider A, DonCarlos LL, Breedlove SM, Jordan CL. Astrocytes in the rat medial amygdala are responsive to adult androgens. J Comp Neurol. 2012;520(11):2531&#x2013;2544</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4209966</ArticleId><ArticleId IdType="pubmed">22581688</ArticleId></ArticleIdList></Reference><Reference><Citation>Oki K, Wiseman RW, Breedlove SM, Jordan CL. Androgen receptors in muscle fibers induce rapid loss of force but not mass: implications for spinal bulbar muscular atrophy. Muscle Nerve. 2013;47(6):823&#x2013;834</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4015727</ArticleId><ArticleId IdType="pubmed">23629944</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Z, Dadgar N, Albertelli M, et al. Abnormalities of germ cell maturation and sertoli cell cytoskeleton in androgen receptor 113 CAG knock-in mice reveal toxic effects of the mutant protein. Am J Pathol. 2006;168(1):195&#x2013;204</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1592669</ArticleId><ArticleId IdType="pubmed">16400023</ArticleId></ArticleIdList></Reference><Reference><Citation>Neri R, Florance K, Koziol P, Van Cleave S. A biological profile of a nonsteroidal antiandrogen, SCH 13521 (4&#x2032;-nitro-3&#x2032;trifluoromethylisobutyranilide). Endocrinology. 1972;91(2):427&#x2013;437</Citation><ArticleIdList><ArticleId IdType="pubmed">4264731</ArticleId></ArticleIdList></Reference><Reference><Citation>Simard J, Luthy I, Guay J, Belanger A, Labrie F. Characteristics of interaction of the antiandrogen flutamide with the androgen receptor in various target tissues. Mol Cell Endocrinol. 1986;44(3):261&#x2013;270</Citation><ArticleIdList><ArticleId IdType="pubmed">3956856</ArticleId></ArticleIdList></Reference><Reference><Citation>Kemppainen JA, Langley E, Wong CI, Bobseine K, Kelce WR, Wilson EM. Distinguishing androgen receptor agonists and antagonists: distinct mechanisms of activation by medroxyprogesterone acetate and dihydrotestosterone. Mol Endocrinol. 1999;13(3):440&#x2013;454</Citation><ArticleIdList><ArticleId IdType="pubmed">10077001</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitt B, Wilt TJ, Schellhammer PF, et al. Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review. Urology. 2001;57(4):727&#x2013;732</Citation><ArticleIdList><ArticleId IdType="pubmed">11306391</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosco DA, Morfini G, Karabacak NM, et al. Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS. Nat Neurosci. 2010;13(11):1396&#x2013;1403</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2967729</ArticleId><ArticleId IdType="pubmed">20953194</ArticleId></ArticleIdList></Reference><Reference><Citation>Singleton AB, Farrer M, Johnson J, et al. &#x3b1;-Synuclein locus triplication causes Parkinson's disease. Science. 2003;302(5646):841.</Citation><ArticleIdList><ArticleId IdType="pubmed">14593171</ArticleId></ArticleIdList></Reference><Reference><Citation>Nedelsky NB, Pennuto M, Smith RB, et al. Native functions of the androgen receptor are essential to pathogenesis in a Drosophila model of spinobulbar muscular atrophy. Neuron. 2010;67(6):936&#x2013;952</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3514079</ArticleId><ArticleId IdType="pubmed">20869592</ArticleId></ArticleIdList></Reference><Reference><Citation>Mo K, Razak Z, Rao P, et al. Microarray analysis of gene expression by skeletal muscle of three mouse models of Kennedy disease/spinal bulbar muscular atrophy. PLoS One. 2010;5(9):e12922.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2944863</ArticleId><ArticleId IdType="pubmed">20886071</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariotti C, Castellotti B, Pareyson D, et al. Phenotypic manifestations associated with CAG-repeat expansion in the androgen receptor gene in male patients and heterozygous females: a clinical and molecular study of 30 families. Neuromuscul Disord. 2000;10(6):391&#x2013;397</Citation><ArticleIdList><ArticleId IdType="pubmed">10899444</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferlini A, Patrosso MC, Guidetti D, et al. Androgen receptor gene (CAG)n repeat analysis in the differential diagnosis between Kennedy disease and other motoneuron disorders. Am J Med Genet. 1995;55(1):105&#x2013;111</Citation><ArticleIdList><ArticleId IdType="pubmed">7702080</ArticleId></ArticleIdList></Reference><Reference><Citation>Johansen JA, Breedlove SM, Jordan CL. Androgen receptor expression in the levator ani muscle of male mice. J Neuroendocrinol. 2007;19(10):823&#x2013;826</Citation><ArticleIdList><ArticleId IdType="pubmed">17850465</ArticleId></ArticleIdList></Reference><Reference><Citation>Monks DA, O'Bryant EL, Jordan CL. Androgen receptor immunoreactivity in skeletal muscle: enrichment at the neuromuscular junction. J Comp Neurol. 2004;473(1):59&#x2013;72</Citation><ArticleIdList><ArticleId IdType="pubmed">15067718</ArticleId></ArticleIdList></Reference><Reference><Citation>Monks DA, Kopachik W, Breedlove SM, Jordan CL. Anabolic responsiveness of skeletal muscles correlates with androgen receptor protein but not mRNA. Can J Physiol Pharmacol. 2006;84(2):273&#x2013;277</Citation><ArticleIdList><ArticleId IdType="pubmed">16900954</ArticleId></ArticleIdList></Reference><Reference><Citation>Montie HL, Cho MS, Holder L, et al. Cytoplasmic retention of polyglutamine-expanded androgen receptor ameliorates disease via autophagy in a mouse model of spinal and bulbar muscular atrophy. Hum Mol Genet. 2009;18(11):1937&#x2013;1950</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2678926</ArticleId><ArticleId IdType="pubmed">19279159</ArticleId></ArticleIdList></Reference><Reference><Citation>Bailey CK, Andriola IF, Kampinga HH, Merry DE. Molecular chaperones enhance the degradation of expanded polyglutamine repeat androgen receptor in a cellular model of spinal and bulbar muscular atrophy. Hum Mol Genet. 2002;11(5):515&#x2013;523</Citation><ArticleIdList><ArticleId IdType="pubmed">11875046</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M, Chevalier-Larsen ES, Merry DE, Diamond MI. Soluble androgen receptor oligomers underlie pathology in a mouse model of spinobulbar muscular atrophy. J Biol Chem. 2007;282(5):3157&#x2013;3164</Citation><ArticleIdList><ArticleId IdType="pubmed">17121819</ArticleId></ArticleIdList></Reference><Reference><Citation>Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature. 2004;431(7010):805&#x2013;810</Citation><ArticleIdList><ArticleId IdType="pubmed">15483602</ArticleId></ArticleIdList></Reference><Reference><Citation>Kemppainen JA, Lane MV, Sar M, Wilson EM. Androgen receptor phosphorylation, turnover, nuclear transport, and transcriptional activation. Specificity for steroids and antihormones. J Biol Chem. 1992;267(2):968&#x2013;974</Citation><ArticleIdList><ArticleId IdType="pubmed">1730684</ArticleId></ArticleIdList></Reference><Reference><Citation>Walcott JL, Merry DE. Ligand promotes intranuclear inclusions in a novel cell model of spinal and bulbar muscular atrophy. J Biol Chem. 2002;277(52):50855&#x2013;50859</Citation><ArticleIdList><ArticleId IdType="pubmed">12388541</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong CI, Zhou ZX, Sar M, Wilson EM. Steroid requirement for androgen receptor dimerization and DNA binding. Modulation by intramolecular interactions between the NH2-terminal and steroid-binding domains. J Biol Chem. 1993;268(25):19004&#x2013;19012</Citation><ArticleIdList><ArticleId IdType="pubmed">8360187</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon HG, Wong J. The corepressors silencing mediator of retinoid and thyroid hormone receptor and nuclear receptor corepressor are involved in agonist- and antagonist-regulated transcription by androgen receptor. Mol Endocrinol. 2006;20(5):1048&#x2013;1060</Citation><ArticleIdList><ArticleId IdType="pubmed">16373395</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang Y, Myers M, Brown M. Formation of the androgen receptor transcription complex. Mol Cell. 2002;9(3):601&#x2013;610</Citation><ArticleIdList><ArticleId IdType="pubmed">11931767</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao G, Chen LY, Zhang A, et al. Regulation of androgen receptor activity by the nuclear receptor corepressor SMRT. J Biol Chem. 2003;278(7):5052&#x2013;5061</Citation><ArticleIdList><ArticleId IdType="pubmed">12441355</ArticleId></ArticleIdList></Reference><Reference><Citation>Lieberman AP, Harmison G, Strand AD, Olson JM, Fischbeck KH. Altered transcriptional regulation in cells expressing the expanded polyglutamine androgen receptor. Hum Mol Genet. 2002;11(17):1967&#x2013;1976</Citation><ArticleIdList><ArticleId IdType="pubmed">12165558</ArticleId></ArticleIdList></Reference><Reference><Citation>Montie HL, Pestell RG, Merry DE. SIRT1 modulates aggregation and toxicity through deacetylation of the androgen receptor in cell models of SBMA. J Neurosci. 2011;31(48):17425&#x2013;17436</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6088793</ArticleId><ArticleId IdType="pubmed">22131404</ArticleId></ArticleIdList></Reference><Reference><Citation>Picard F, Kurtev M, Chung N, et al. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature. 2004;429(6993):771&#x2013;776</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2820247</ArticleId><ArticleId IdType="pubmed">15175761</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu M, Wang C, Reutens AT, et al. p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation. J Biol Chem. 2000;275(27):20853&#x2013;20860</Citation><ArticleIdList><ArticleId IdType="pubmed">10779504</ArticleId></ArticleIdList></Reference><Reference><Citation>Langley E, Zhou ZX, Wilson EM. Evidence for an anti-parallel orientation of the ligand-activated human androgen receptor dimer. J Biol Chem. 1995;270(50):29983&#x2013;29990</Citation><ArticleIdList><ArticleId IdType="pubmed">8530400</ArticleId></ArticleIdList></Reference><Reference><Citation>He B, Bowen NT, Minges JT, Wilson EM. Androgen-induced NH2- and COOH-terminal Interaction inhibits p160 coactivator recruitment by activation function 2. J Biol Chem. 2001;276(45):42293&#x2013;42301</Citation><ArticleIdList><ArticleId IdType="pubmed">11551963</ArticleId></ArticleIdList></Reference><Reference><Citation>Guidetti D, Vescovini E, Motti L, et al. X-linked bulbar and spinal muscular atrophy, or Kennedy disease: clinical, neurophysiological, neuropathological, neuropsychological and molecular study of a large family. J Neurol Sci. 1996;135(2):140&#x2013;148</Citation><ArticleIdList><ArticleId IdType="pubmed">8867070</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy WR, Alter M, Sung JH. Progressive proximal spinal and bulbar muscular atrophy of late onset. A sex-linked recessive trait. Neurology. 1968;18(7):671&#x2013;680</Citation><ArticleIdList><ArticleId IdType="pubmed">4233749</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>